Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Haplocord Hct

Research Leaders

5 sponsors active, led by Zhejiang University

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 1 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 3 (1)

Trial Status

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (1)

Showing 1 of 1 trials
NCT03719534Phase 3Completed

Haplo HCT vs Haplo-cord HCT for Patients With AML

Showing all 1 trials

Research Network

Common Treatments

  • Haplocord Hct1
  • Haplohct1

Active Sponsors

  • Zhejiang University1
  • Hygeia Suzhou Yongding Hospital1
  • The Second People's Hospital of Huai'an1
  • The First Affiliated Hospital of Soochow University1
  • Soochow Hopes Hematology Hospital1

Top Investigators

Related Conditions

  • Acute Myeloid Leukemia1
  • Haploidentical Donor1
  • Hematopoietic Stem Cell Transplantation1

Activity Timeline